Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc (TOVX)
1.2600 x 6 1.4500 x 10
Post-market by (Cboe BZX)
1.3992 +0.0892 (+6.81%) 04/22/25 [NYSE Arca]
1.2600 x 6 1.4500 x 10
Post-market 1.3992 unch (unch) 16:10 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3008
Day High
1.4700
Open 1.3600
Previous Close 1.3100 1.3100
Volume 16,975 16,975
Avg Vol 22,074 22,074
Stochastic %K 76.09% 76.09%
Weighted Alpha -68.39 -68.39
5-Day Change -0.0508 (-3.50%) -0.0508 (-3.50%)
52-Week Range 0.9563 - 12.2775 0.9563 - 12.2775
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,645
  • Shares Outstanding, K 2,782
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,650 K
  • EBIT $ -21 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9563 +46.31%
on 04/09/25
Period Open: 1.2200
1.4800 -5.46%
on 04/15/25
+0.1792 (+14.69%)
since 03/21/25
3-Month
0.9563 +46.31%
on 04/09/25
Period Open: 1.4400
1.7500 -20.05%
on 02/19/25
-0.0408 (-2.83%)
since 01/22/25
52-Week
0.9563 +46.31%
on 04/09/25
Period Open: 10.2750
12.2775 -88.60%
on 05/09/24
-8.8758 (-86.38%)
since 04/22/24

Most Recent Stories

More News
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

TOVX : 1.3992 (+6.81%)
Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal...

TOVX : 1.3992 (+6.81%)
Therivaâ„¢ Biologics to Present at the 2025 NeauxCancer Conference

TOVX : 1.3992 (+6.81%)
Q1 Virtual Investor Summit: On-Demand Presentations Now Live

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors...

SNANF : 0.1950 (+1.67%)
BRNS : 0.7600 (+7.04%)
FEMY : 1.2200 (+1.67%)
PERF : 1.6500 (+2.48%)
DRTS : 2.62 (-0.76%)
GIFT : 1.7400 (+1.75%)
ROYIF : 0.0403 (+34.33%)
ZCAR : 3.68 (+16.46%)
CLNN : 2.98 (-1.32%)
MIND : 5.44 (+3.42%)
PYPD : 2.71 (-1.45%)
TOVX : 1.3992 (+6.81%)
Therivaâ„¢ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

TOVX : 1.3992 (+6.81%)
Therivaâ„¢ Biologics to Participate in the Q1 Investor Summit Virtual

TOVX : 1.3992 (+6.81%)
Theriva Biologics Receives FDA Guidance for Phase 3 Study of VCN-01 in Metastatic Pancreatic Adenocarcinoma

Theriva Biologics received FDA guidance on VCN-01's Phase 3 study for metastatic pancreatic cancer treatment, optimizing trial design.Quiver AI SummaryTheriva Biologics has announced the outcomes of a...

TOVX : 1.3992 (+6.81%)
Therivaâ„¢ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

TOVX : 1.3992 (+6.81%)
Therivaâ„¢ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results

TOVX : 1.3992 (+6.81%)
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

TOVX : 1.3992 (+6.81%)

Business Summary

Theriva Biologics Inc. is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company's lead candidate includes VCN-01, SYN-004 and SYN-020. Theriva Biologics Inc., formerly known as Synthetic Biologics Inc., is based in ROCKVILLE,...

See More

Key Turning Points

3rd Resistance Point 1.6484
2nd Resistance Point 1.5592
1st Resistance Point 1.4792
Last Price 1.3992
1st Support Level 1.3100
2nd Support Level 1.2208
3rd Support Level 1.1408

See More

52-Week High 12.2775
Fibonacci 61.8% 7.9528
Fibonacci 50% 6.6169
Fibonacci 38.2% 5.2810
Last Price 1.3992
52-Week Low 0.9563

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro